FIA
IMPL

FNY Investment Advisers’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

FNY Investment Advisers’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,377
Closed -$65K – 873
2021
Q3 		$65K Buy
+5,377
New +$78K 0.03% 289

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FNY Investment Advisers's IMPL Position: Q4 2021 in Review

FNY Investment Advisers sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2021, closing a stake of 5,377 shares — an estimated $65K sold.

FNY Investment Advisers first reported a position in IMPL in Q3 2021 and held it in 1 quarter. The position peaked at $65K in Q3 2021. 45 funds tracked by Wall St. Rank hold IMPL as of Q4 2021.

  • FNY Investment Advisers reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • FNY Investment Advisers sold 5,377 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2021, an estimated $65K.
  • FNY Investment Advisers first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • FNY Investment Advisers's Impel Pharmaceuticals Inc. Common Stock position peaked at $65K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2021.

Based on FNY Investment Advisers's 13F filing for Q4 2021, filed 10 Jan 2022.